Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SITIME CorpSITM · Entity 1138 | See Remarks | September 11, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SITIME Corp
Report date September 11, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,997 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 3,000 · Balance 44,997 F1: Includes an aggregate of 29,322 shares of common stock issuable pursuant to previously reported restricted stock units and performance-based restricted stock units that have not vested. These unvested units include 12,698 restricted stock units that vest over time, and 16,624 performance-based restricted stock units that vest based on certain absolute and relative price performance of the issuer's common stock over various performance periods. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 29,322 shares of common stock issuable pursuant to previously reported restricted stock units and performance-based restricted stock units that have not vested. These unvested units include 12,698 restricted stock units that vest over time, and 16,624 performance-based restricted stock units that vest based on certain absolute and relative price performance of the issuer's common stock over various performance periods.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CAVIUM, INC.
Report date July 06, 2018 · Filed July 06, 2018
Section 16 reporting ended · disclosed 2018-07-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-07-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-07-06 · Other · Disposed 7,664 · Balance 41,383 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. Row 2 · 2018-07-06 · Disposition to issuer · Disposed 34,947 · Balance 6,436 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F2: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"), the vesting of which was fully accelerated immediately prior to the effective time of the Merger (the "Effective Time"). F3: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and vested RSU and each outstanding RSU held by non-employee directors, whether vested or unvested, was converted into the right to receive (x) an amount in cash equal to the product of (A) $40.00 multiplied by (B) the number of shares of Company common stock subject to such RSU and (y) a number of shares of Marvell common stock equal to (1) 2.1757 multiplied by (2) the number of shares of Company common stock subject to such RSU. Row 3 · 2018-07-06 · Disposition to issuer · Disposed 2,461 · Balance 3,975 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F4: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"), the vesting of which was fully accelerated immediately prior to the Effective Time. F5: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and vested PRSU was converted into the right to receive (x) an amount in cash equal to the product of (A) $40.00 multiplied by (B) the number of shares of Company common stock subject to such PRSU and (y) a number of shares of Marvell common stock equal to (1) 2.1757 multiplied by (2) the number of shares of Company common stock subject to such PRSU. Row 4 · 2018-07-06 · Disposition to issuer · Disposed 3,975 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F4: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"), the vesting of which was fully accelerated immediately prior to the Effective Time. F5: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and vested PRSU was converted into the right to receive (x) an amount in cash equal to the product of (A) $40.00 multiplied by (B) the number of shares of Company common stock subject to such PRSU and (y) a number of shares of Marvell common stock equal to (1) 2.1757 multiplied by (2) the number of shares of Company common stock subject to such PRSU. |
| Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $62.86 · Expires 2022-02-16 | Direct | 0 |
Reported balance
After 2018-07-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-06 · Disposition to issuer · Disposed 5,250 · Balance 0 F6: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 7) F7: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339). |
| Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $48.88 · Expires 2023-02-11 | Direct | 0 |
Reported balance
After 2018-07-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-06 · Disposition to issuer · Disposed 15,365 · Balance 0 F6: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 7) F7: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339). |
| Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $65.80 · Expires 2024-02-10 | Direct | 0 |
Reported balance
After 2018-07-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-07-06 · Disposition to issuer · Disposed 11,464 · Balance 0 F6: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 7) F7: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018.
F2: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"), the vesting of which was fully accelerated immediately prior to the effective time of the Merger (the "Effective Time").
F3: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and vested RSU and each outstanding RSU held by non-employee directors, whether vested or unvested, was converted into the right to receive (x) an amount in cash equal to the product of (A) $40.00 multiplied by (B) the number of shares of Company common stock subject to such RSU and (y) a number of shares of Marvell common stock equal to (1) 2.1757 multiplied by (2) the number of shares of Company common stock subject to such RSU.
F4: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"), the vesting of which was fully accelerated immediately prior to the Effective Time.
F5: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and vested PRSU was converted into the right to receive (x) an amount in cash equal to the product of (A) $40.00 multiplied by (B) the number of shares of Company common stock subject to such PRSU and (y) a number of shares of Marvell common stock equal to (1) 2.1757 multiplied by (2) the number of shares of Company common stock subject to such PRSU.
F6: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 7)
F7: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2018 Filed Mar 1, 2018 16:29 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 8,228 | $90.01 | $740,602.28 |
DisclosureSEC source: 0001209191-18-015033 · doc4.xml · nonDerivative · entry 3 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,486 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $90.00 per share to $90.03 per share. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:29 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon stock | 1,637 | $37.63 | $61,600.31 |
DisclosureSEC source: 0001209191-18-015033 · doc4.xml · nonDerivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:29 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon stock | 500 | $37.83 | $18,915.00 |
DisclosureSEC source: 0001209191-18-015033 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:32 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 8,000 | $87.19 | $697,520.00 |
DisclosureSEC source: 0001209191-18-012037 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,577 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $86.42 per share to $87.62 per share. Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 17:26 UTC | CAVIUM, INC. CAVM · Entity 165173 | GrantCommon stock | 4,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-006530 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,577 F1 · kind: On February 10, 2017, pursuant to Cavium's 2016 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person equally on January 31, 2018 and January 31, 2019. As determined by Cavium's Compensation Committee, the performance criteria was met at a level that caused 4,922 shares to be earned, and the reporting person received 2,461 shares of Cavium's common stock at no cost on January 31, 2018. The remaining 2,461 shares of Cavium's common stock will vest and delivered to the reporting person at no cost on January 31, 2019. F1 · price: On February 10, 2017, pursuant to Cavium's 2016 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person equally on January 31, 2018 and January 31, 2019. As determined by Cavium's Compensation Committee, the performance criteria was met at a level that caused 4,922 shares to be earned, and the reporting person received 2,461 shares of Cavium's common stock at no cost on January 31, 2018. The remaining 2,461 shares of Cavium's common stock will vest and delivered to the reporting person at no cost on January 31, 2019. Read SEC document |
| January 19, 2018 Filed Jan 22, 2018 18:25 UTC | CAVIUM, INC. CAVM · Entity 165173 | GrantCommon stock | 12,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-004797 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,655 F1 · kind: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2019 and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive on share of Cavium's common stock at no cost. F1 · price: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2019 and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive on share of Cavium's common stock at no cost. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 16:19 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionStock option right to buy · Derivative | 15,000 | $0.00 Strike: $37.22 | $0.00 |
DisclosureSEC source: 0001209191-17-060291 · doc4.xml · derivative · entry 3 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 15,000 shares Expires 2018-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 16:19 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 15,000 | $77.22 | $1,158,300.00 |
DisclosureSEC source: 0001209191-17-060291 · doc4.xml · nonDerivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 16:19 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon stock | 15,000 | $37.22 | $558,300.00 |
DisclosureSEC source: 0001209191-17-060291 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 17:45 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionSTock option right to buy · Derivative | 15,000 | $0.00 Strike: $35.73 | $0.00 |
DisclosureSEC source: 0001209191-17-033696 · doc4.xml · derivative · entry 3 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document |
| May 16, 2017 Filed May 18, 2017 17:45 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon Stock | 15,000 | $75.73 | $1,135,950.00 |
DisclosureSEC source: 0001209191-17-033696 · doc4.xml · nonDerivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. Read SEC document |
| May 16, 2017 Filed May 18, 2017 17:45 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon Stock | 15,000 | $35.73 | $535,950.00 |
DisclosureSEC source: 0001209191-17-033696 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:28 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionStock option right to buy · Derivative | 15,000 | $0.00 Strike: $37.22 | $0.00 |
DisclosureSEC source: 0001209191-17-021092 · doc4.xml · derivative · entry 3 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires 2018-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:28 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 15,000 | $72.22 | $1,083,300.00 |
DisclosureSEC source: 0001209191-17-021092 · doc4.xml · nonDerivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:28 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon stock | 15,000 | $37.22 | $558,300.00 |
DisclosureSEC source: 0001209191-17-021092 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:52 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionStock option right to buy · Derivative | 15,000 | $0.00 Strike: $37.22 | $0.00 |
DisclosureSEC source: 0001209191-17-017680 · doc4.xml · derivative · entry 3 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 15,000 shares Expires 2018-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:52 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 15,000 | $67.22 | $1,008,300.00 |
DisclosureSEC source: 0001209191-17-017680 · doc4.xml · nonDerivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:52 UTC | CAVIUM, INC. CAVM · Entity 165173 | Exercise / conversionCommon stock | 15,000 | $37.22 | $558,300.00 |
DisclosureSEC source: 0001209191-17-017680 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 19:06 UTC | CAVIUM, INC. CAVM · Entity 165173 | GrantStock option right to buy · Derivative | 11,464 | $0.00 Strike: $65.80 | $0.00 |
DisclosureSEC source: 0001209191-17-010207 · doc4.xml · derivative · entry 2 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,464 Underlying: Common stock · 11,464 shares Expires 2024-02-10 F2 · kind: This grant has a 4-year vesting term. 1/4 of the shares subject to the option vest on the first year anniversary of the grant date and the remaining shares will vest monthly thereafter over the next three years. F2 · derivative.exercise_date: This grant has a 4-year vesting term. 1/4 of the shares subject to the option vest on the first year anniversary of the grant date and the remaining shares will vest monthly thereafter over the next three years. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 19:06 UTC | CAVIUM, INC. CAVM · Entity 165173 | GrantCommon stock | 13,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-010207 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 F1 · kind: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2018; and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive one share of Cavium's common stock at no cost. F1 · price: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2018; and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive one share of Cavium's common stock at no cost. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 18:14 UTC | CAVIUM, INC. CAVM · Entity 165173 | SaleCommon stock | 25,000 | $66.95 | $1,673,750.00 |
DisclosureSEC source: 0001209191-17-008434 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,970 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $66.50 per share to $67.23 per share. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 19:20 UTC | CAVIUM, INC. CAVM · Entity 165173 | GrantCommon stock | 9,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-007319 · doc4.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · SVP,Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,970 F1 · kind: On February 11, 2016, pursuant to Cavium's 2007 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person on January 31, 2017. As determined by Cavium's Compensation Committee on January 27, 2017, the performance criteria was met at a level that caused 9,232 shares to vest, and the reporting person received the same number of shares of Cavium's common stock at no cost. F1 · price: On February 11, 2016, pursuant to Cavium's 2007 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person on January 31, 2017. As determined by Cavium's Compensation Committee on January 27, 2017, the performance criteria was met at a level that caused 9,232 shares to vest, and the reporting person received the same number of shares of Cavium's common stock at no cost. Read SEC document |
| February 13, 2013 Filed Feb 16, 2023 02:42 UTC | SITIME Corp SITM · Entity 1138 | GrantCommon Stock | 619 | $0.00 | $0.00 |
DisclosureSEC source: 0001451809-23-000012 · primary_doc.xml · nonDerivative · entry 1 Pangrazio Vincent P · CIK 0001514114 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,016 F1 · shares: Restricted stock unit award under the Executive Bonus and Retention Plan vesting as to 50% of the shares on February 20, 2023 and the remaining 50% of the shares on August 20, 2023. F2 · balance_after: Includes an aggregate of 71,707 shares of common stock issuable pursuant to previously reported restricted stock units and performance-based restricted stock units and that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.